CLINICAL TRIALS PROFILE FOR BENDAMUSTINE HYDROCHLORIDE

505(b)(2) Clinical Trials for BENDAMUSTINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00974233 ↗	Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL	Completed	Celgene Corporation	Phase 2	2009-10-01	The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination	NCT00974233 ↗	Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL	Completed	University of Wisconsin, Madison	Phase 2	2009-10-01	The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Formulation	NCT02162888 ↗	A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients	Completed	Eagle Pharmaceuticals, Inc.	Phase 1	2013-11-01	The purpose of this study is to demonstrate that a new formulation of an Bendamustine (BDM) Hydrochloride (HCl) is bioequivalent (BE) (similar) to the commercially available product in patients with cancer.

All Clinical Trials for BENDAMUSTINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00069758 ↗	Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma	Completed	Cephalon	Phase 2	2003-09-01	Summary: As this is an open label study, all patients will receive SDX-105 by 30-60 minute intravenous infusion on day 1 and day 2. Treatment will repeat every 21 days. Treatment can continue for up to one year in the absence of disease progression or unacceptable toxicity. Patients will be followed until disease progression. Rationale: Drugs used in chemotherapy, such as SDX-105, use different ways to stop tumor cells from dividing so they stop growing or die. Purpose: This study will evaluate the effectiveness and safety in non-Hodgkin's lymphoma in patients who are refractory to Rituxan.
NCT00076349 ↗	SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)	Completed	Cephalon	Phase 2	2004-04-01	SUMMARY: This is an open label study combining Rituxan and SDX-105. Rituxan will be given on day 1 followed by a 30-60 minute intravenous infusion of SDX-105 on day 2 and day 3. Treatment will repeat every 21 days (a cycle). Treatment can continue for up to 6 cycles (about 4 months) if tumor status improves and there are no unacceptable side effects. Patients will be followed for up to 2 years or until disease progression. RATIONALE: Rituxan has been shown to increase the sensitivity of cells to chemotherapy. The combination of SDX-105 and Rituxan has been effective in both the laboratory and in a recent clinical study with Non-Hodgkin's lymphoma patients. PURPOSE: This study will evaluate the safety and effectiveness of SDX-105 plus Rituxan in patients with Non-Hodgkin's lymphoma who have relapsed after taking Rituxan.
NCT00139841 ↗	Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab	Completed	Cephalon	Phase 3	2005-10-01	SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a defined timeframe after taking rituximab (Rituxan®). Treanda will be given via 60-minute intravenous infusion on days 1 and 2 of every 21-day treatment cycle. Patients will be treated for 6 cycles unless they develop progressive disease or unacceptable toxicity. Those who continue to receive clinical benefit at end of 6 cycles may receive an additional 2 cycles. Following the end of treatment, patients will be followed for up to 2 years until disease progression or start of another anti-cancer therapy.
NCT00274963 ↗	Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Completed	German CLL Study Group	Phase 2	2004-10-01	RATIONALE: Drugs used in chemotherapy, such as bendamustine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bendamustine together with mitoxantrone works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
NCT00274989 ↗	Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia	Completed	University of Cologne	Phase 2	2005-11-01	CLL2M is a phase 2, multicenter, open label study to investigate the possible therapeutic benefits of using bendamustine in combination with rituximab for the treatment of patients with previously untreated or relapsed CLL.
NCT00274989 ↗	Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia	Completed	German CLL Study Group	Phase 2	2005-11-01	CLL2M is a phase 2, multicenter, open label study to investigate the possible therapeutic benefits of using bendamustine in combination with rituximab for the treatment of patients with previously untreated or relapsed CLL.

Clinical Trial Conditions for BENDAMUSTINE HYDROCHLORIDE

Condition Name

Condition Name for BENDAMUSTINE HYDROCHLORIDE
Intervention	Trials
Chronic Lymphocytic Leukemia	54
Mantle Cell Lymphoma	34
Lymphoma	33
Multiple Myeloma	31

Condition MeSH

Condition MeSH for BENDAMUSTINE HYDROCHLORIDE
Intervention	Trials
Lymphoma	230
Leukemia, Lymphocytic, Chronic, B-Cell	95
Leukemia, Lymphoid	86
Leukemia	85

Clinical Trial Locations for BENDAMUSTINE HYDROCHLORIDE

Trials by Country

Trials by Country for BENDAMUSTINE HYDROCHLORIDE
Location	Trials
Italy	286
Spain	148
Canada	133
China	128
Australia	116

Trials by US State

Trials by US State for BENDAMUSTINE HYDROCHLORIDE
Location	Trials
Texas	84
California	84
New York	77
Florida	54
Illinois	53

Clinical Trial Progress for BENDAMUSTINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for BENDAMUSTINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	12
PHASE2	26

Clinical Trial Status

Clinical Trial Status for BENDAMUSTINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	151
Recruiting	97
Active, not recruiting	50

Clinical Trial Sponsors for BENDAMUSTINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for BENDAMUSTINE HYDROCHLORIDE
Sponsor	Trials
National Cancer Institute (NCI)	34
Cephalon	33
Hoffmann-La Roche	22

Sponsor Type

Sponsor Type for BENDAMUSTINE HYDROCHLORIDE
Sponsor	Trials
Other	373
Industry	320
NIH	34

Bendamustine Hydrochloride Clinical Trials Update, Market Analysis, and Future Revenue Projection (2026-2035)

Last updated: July 28, 2026

Bendamustine hydrochloride remains a mature oncology cytotoxic in hematologic malignancies with long-running clinical programs focused on combination regimens, line-of-therapy shifts, and less myelosuppressive delivery strategies. Commercial performance is driven by continued uptake in indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL), with incremental growth tied to guideline positioning, biosurvivorship (survival) outcomes in combination trials, and geography-specific reimbursement.

---

How are bendamustine hydrochloride clinical trials progressing in 2025-2026?

Status snapshot (high-level): Clinical activity concentrates in (1) combinations with anti-CD20 agents, (2) combinations with BTK inhibitors and BCL2-axis therapies, (3) post-transplant and relapse settings, and (4) novel delivery or dose-scheduling strategies to maintain efficacy with manageable toxicity. Trial outcomes that most affect market share are those demonstrating improved depth of response (ORR/CR rates), progression-free survival (PFS), and tolerability that enables earlier-line use.

Which indications dominate bendamustine trial activity?

Core therapeutic focus

• Indolent non-Hodgkin lymphoma (follicular lymphoma, marginal zone lymphoma, iNHL subtypes)
• Mantle cell lymphoma (especially relapsed/refractory and chemoimmunotherapy-sensitive settings)
• Chronic lymphocytic leukemia (CLL) and CLL-adjacent cohorts (often in combination studies where tolerated)
• Diffuse large B-cell lymphoma (DLBCL) subsets and transformation settings in combination protocols

Trial design patterns that most influence uptake

• Phase 2/3 combination studies aimed at moving regimens earlier in the treatment sequence
• Randomized designs using bendamustine-containing backbone comparisons
• Studies that target MRD and response quality endpoints to support line-of-therapy changes

What endpoints are being used to win market adoption?

Commercially relevant endpoints

• PFS and duration of response (DoR) as primary drivers for payer and guideline adoption
• CR and undetectable MRD (when incorporated) as competitive differentiators versus rituximab-chemotherapy or BTK inhibitor backbones
• Safety endpoints framed around neutropenia, thrombocytopenia, infection rates, and regimen discontinuation

---

What patents protect bendamustine hydrochloride and how do they affect clinical development and generic competition?

Bendamustine hydrochloride is an established active, and market structure is shaped more by patent estate around formulations, dosing regimens, and use patents than by core API monopolies. Patent-driven “clinical development” advantages tend to appear via:

• proprietary formulation or delivery systems (where applicable)
• method-of-use indications (line-of-therapy, combination choices, dosing schedules)
• data exclusivity and regulatory exclusivity around specific labeled regimens

What are typical sources of legal and regulatory exclusivity for bendamustine products?

• Orange Book-listed patents for specific NDA/BLA products
• Formulation patents for lyophilized vs ready-to-dilute presentations and stability claims
• Use patents tied to specific combinations and sequencing

(Note: No product-specific patent numbers, expiration dates, or Orange Book listings were provided in the prompt; the market forecast below is therefore built on competitive, not asset-level, exclusivity assumptions.)

---

What is the Orange Book status of bendamustine hydrochloride (NDA-backed brands vs generics)?

Featured snippet answer: Bendamustine hydrochloride is widely available as generic chemotherapy in the US market, and product differentiation is primarily presentation-level and labeling-level rather than exclusivity-level.

How do generics shape availability and pricing?

• Broad generic penetration typically compresses branded pricing and increases procurement-based switching
• Hospital formularies drive volume, with lower cost and supply reliability acting as primary adoption levers
• Any product that improves shelf-life, reduces reconstitution burden, or improves administration workflow can win by operational advantage even when efficacy is comparable

---

When does bendamustine hydrochloride lose exclusivity in key markets?

Featured snippet answer: Exclusivity is not a single event because bendamustine is an established molecule. Commercial lock-in largely depends on remaining patents tied to specific labeled presentations or labeled combinations, rather than API exclusivity.

What matters most for launch timing for generics and follow-on products?

• Patent expiration for specific NDA submissions and formulation/use patents
• Litigation outcomes affecting FDA approval timing
• Any regulatory exclusivity tied to a specific reformulation or new labeled indication

---

How strong is the patent estate for bendamustine combination regimens vs API competition?

Commercial reality: In oncology cytotoxics, investors and competitors typically benchmark the patent estate around:

• dosing regimens and administration schedules
• combination compatibility claims (e.g., bendamustine with anti-CD20 or other targeted agents)
• supportive-care method-of-use expansions that affect label scope

Adoption impact: Even modest label protection around a combo regimen can sustain share in guideline-based settings where prescribers prefer evidence-backed sequences.

---

What generic entry risks exist for bendamustine hydrochloride?

Risk profile

• High generic likelihood due to maturity of the asset and ongoing manufacturing capacity expansion
• Entry barriers are mostly operational (GMP capacity, cold-chain not relevant, but sterility assurance, batch consistency) and documentation-based rather than scientific novelty
• Risk is concentrated in supply chain resilience and consistent pricing rather than clinical differentiation

---

How does bendamustine hydrochloride compare with alternative NHL and MCL regimens (R-CHOP, R-CVP, ibrutinib/BTK backbones, venetoclax-based combos)?

Key competitive comparisons that drive market share

• Versus R-chemotherapy backbones: bendamustine’s value proposition is often better response depth and shorter exposure for certain cohorts, leading to guideline inclusion
• Versus BTK inhibitor and BCL2-axis approaches: BTK inhibitors can shift usage toward targeted regimens, but chemoimmunotherapy remains standard where rapid cytoreduction and proven efficacy are preferred
• Versus newer cellular therapies: niche, driven by eligibility and sequencing rather than direct line overlap for most payers

Market impact mechanism: If combination trials show durable benefit with acceptable toxicity, bendamustine combinations can retain share even as targeted agents expand.

---

What is the current market size for bendamustine hydrochloride and what growth rate is plausible?

Mature-market baseline: Bendamustine hydrochloride is a chronic revenue contributor with growth driven less by incidence growth and more by:

• regimen sequencing within NHL/MCL
• competitive dynamics among generics and hospital tender dynamics
• adoption shifts from targeted regimens to chemoimmunotherapy in specific subgroups (or vice versa)
• country-level reimbursement updates

Market projection framework (assumptions)

Because the prompt did not include a starting market revenue value, the projection below expresses outcomes as ranges and drivers rather than asserting a single point estimate.

2026-2035 revenue trajectory drivers

1. Volume resilience from NHL/MCL incidence and continued guideline-based use
2. Price compression from generic competition and procurement-driven tendering
3. Regimen mix shifts from targeted therapies (BTK inhibitors, venetoclax-based regimens) partially substituting in some lines
4. Supply and contract stability influencing realized pricing in major hospital systems

Indicative projection ranges (global, ex-US and US treated as combined)

• Base case: low single-digit global CAGR in nominal revenue through early 2030s, turning flat-to-slightly declining in late decade as price compression outweighs any volume growth.
• Downside case: negative nominal CAGR if reimbursement tightens and targeted regimens take larger share in earlier lines.
• Upside case: near-flat or modest positive nominal growth if bendamustine combinations remain entrenched in iNHL/MCL and stable tender pricing holds in major procurement markets.

(These ranges reflect typical behavior of mature generic oncology cytotoxics rather than asset-specific exclusivity.)

---

What commercial segments will expand or contract for bendamustine hydrochloride?

Where demand is most likely to hold

• US hospital and oncology infusion centers with existing chemo protocols for iNHL and MCL
• Regions with established reimbursement pathways for generic chemotherapy and consistent procurement contracts

Where substitution pressure is highest

• Earlier-line shifts toward targeted regimens if new clinical readouts favor BTK or BCL2-axis backbones with better tolerability
• Subgroups where oral targeted therapy is preferred due to reduced infusion clinic utilization

---

What clinical readouts could change bendamustine uptake over the next 24 months?

High-signal trial results to monitor

• Randomized studies showing PFS improvement or non-inferiority with improved safety enabling broader adoption
• Trials where bendamustine combinations demonstrate better response quality and reduced treatment discontinuation
• Studies supporting move into earlier lines for iNHL or into specific biomarker-defined groups

Adoption bottlenecks

• Toxicity profiles that raise supportive-care costs
• Logistical complexity if combinations require additional monitoring
• Evidence quality that payers use to justify coverage against effective targeted regimens

---

How do manufacturing and supply considerations affect market outcomes for bendamustine?

Key determinants

• Sterile injectable capacity and compliance record
• Batch consistency and impurities control for cytotoxics
• Distribution reliability to infusion centers that run scheduled regimens

Pricing linkage

• Where supply tightness exists, realized pricing can temporarily rebound.
• Over time, multiple entrants typically drive normalized low pricing across tenders.

---

Timeline: Clinical and market catalysts to watch (2026-2035)

Year	Clinical catalyst type	Market implication
2026-2027	Readouts for combination regimens in iNHL/MCL and safety-focused endpoints	Maintains or modestly reallocates share by line-of-therapy
2027-2029	Follow-on data for response durability and sequencing	Can shift guideline positioning and payer acceptance
2029-2031	Long-term PFS/DoR and subgroup analyses	Determines whether bendamustine stays entrenched or loses earlier-line share
2031-2035	Mature competition outcomes among generic suppliers	Sets realized pricing trajectory and stability

---

Competitive landscape: Who are the likely commercial drivers for bendamustine hydrochloride?

Competitive dynamics (typical)

• Multiple generic manufacturers compete primarily on price, contract terms, and supply reliability
• Any differentiation in labeled indication scope or formulation handling affects formulary preference

Investor and business relevance

• Contracts with group purchasing organizations and major hospital networks dominate volume outcomes
• Any regulatory or quality event can cause short-term procurement disruptions that affect realized price

(No manufacturer list was provided in the prompt. The analysis above therefore does not name specific companies.)

---

Key Takeaways

• Bendamustine hydrochloride remains clinically relevant in iNHL and MCL with ongoing trial focus on combination regimens, sequencing, and toxicity management.
• Commercial growth is constrained by maturity and generic penetration, so nominal revenue is more sensitive to price compression than to incidence-driven demand.
• The most valuable near-term clinical signals are PFS and response-quality readouts that support line-of-therapy expansion despite substitution by targeted agents.
• Market outcomes through 2035 are expected to follow a low-growth-to-flat-to-slightly declining pattern in nominal terms under typical generic tender dynamics.

---

FAQs

1. Do bendamustine combinations increase infection risk compared with bendamustine monotherapy in iNHL?
2. How do bendamustine dosing schedules affect hospitalization rates and treatment discontinuation in community oncology?
3. What lines of therapy most influence bendamustine hydrochloride utilization in mantle cell lymphoma?
4. When targeted therapies substitute for bendamustine, which patient subgroups typically remain chemo-sensitive?
5. How do tender cycles and hospital formulary updates change bendamustine generic pricing in the US?

---

References

1. (No cited sources were provided in the prompt; no external sources were used.)